NCT03269669 2026-03-18
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT06043323 2026-03-12
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04542824 2026-03-03
EPCORE™ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-03-03
EPCORE™ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT06191744 2026-03-03
EPCORE™FL-2
Genmab
Phase 3 Recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT06911502 2025-12-05
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed